Ru58841 2000mg topical vial
Certificate of Analysis available on request for the current lot.
Complete the setup
Reconstitution and bench supplies researchers pair with Ru58841 2000mg topical vial
NOT FOR HUMAN CONSUMPTION
RU58841 is a topical, non-steroidal androgen-receptor (AR) antagonist investigated for androgenetic alopecia (AGA). It competitively blocks DHT/testosterone at the follicular AR without inhibiting 5-α-reductase or lowering systemic androgens, aiming for local antiandrogen activity with minimal systemic exposure. It is not approved by any major regulator; most human data come from small early-phase studies and patents. It’s commonly sold online as a research chemical of variable quality.
Additional Benefits of RU58841 Now Under Investigation
| Benefit | Key take-aways |
|---|---|
| 1 Scalp-localized AR blockade | Designed to antagonize AR within hair follicles, reducing miniaturization drivers while preserving serum DHT/Testosterone, unlike oral 5-AR inhibitors. |
| 2 Hair-count/diameter signals | Early clinical and preclinical work reported increased terminal-hair counts and shaft thickeningversus vehicle in male-pattern hair loss; magnitude appears modest to moderate and dose-dependent. |
| 3 Rapid onset vs systemic options | Some datasets show visible shedding slowdown/diameter gains by ~3–6 months, consistent with localized signaling change rather than endocrine remodeling. |
| 4 Add-on to standard care | Mechanistically complements minoxidil (growth-phase stimulation) and finasteride/dutasteride(DHT reduction), potential stacking to reduce required oral 5-ARI dose. |
| 5 Female AGA potential | As a non-hormone topical AR blocker, RU58841 is conceptually attractive for female-pattern hair loss where 5-ARIs are often avoided; formal trials are lacking. |
| 6 Sebum/scalp oil | AR blockade may reduce sebaceous activity, improving scalp oiliness, evidence is anecdotal/limited. |
| 7 Post-transplant maintenance | Hypothesized to protect native hairs around grafts when oral 5-ARIs are not tolerated. Evidence is extrapolative. |
| 8 Hyperandrogenic niches | The AR-topical approach is being explored conceptually for acne/seborrhea; RU58841 data are minimal, but class logic supports testing. |
| 9 Quality-of-life | Hair density/diameter improvements correlate with appearance satisfaction; validated PRO data for RU58841 specifically are scarce. |
2. Molecular Mechanism of Action
2.1 Receptor pharmacodynamics
-
Target: Androgen receptor (AR) competitive antagonist (non-steroidal, flutamide/bicalutamide-like scaffold).
-
Follicular action: Blocks DHT-bound AR signaling in dermal papilla cells, down-shifting transcription of TGF-β, DKK-1, and pro-miniaturization genes, helping maintain anagen and shaft caliber.
-
Selectivity goal: High local AR occupancy with low systemic levels when delivered as a topical solution.
2.2 Down-stream biology
| Pathway | Functional outcome | Context |
|---|---|---|
| AR antagonism | ↓ Miniaturization signaling | Hair follicle DP/ORS |
| Paracrine growth factors | ↑ Pro-anagen milieu (VEGF/IGF-1 balance) | Peri-follicular |
| Sebocyte AR tone | ↓ Sebum output (theoretical) | Scalp skin |
3. Pharmacokinetics (what’s known)
-
Route: Topical solution (commonly 5–10% in ethanol/PG or glycol vehicles in research use).
-
Absorption: Low systemic exposure reported in early studies at clinical doses; depends heavily on vehicle, % concentration, scalp integrity, and application area.
-
Metabolism: Rapid local distribution; specific human metabolites are poorly characterized in public literature.
-
Dosing used in studies: Once-daily topical application; dose-finding suggested ~50–100 mg/day ranges in legacy programs.
4. Evidence Summary
-
Preclinical: In hamsters/macaques, topical RU58841 prevented androgen-driven alopecia and restored hair density vs vehicle.
-
Human (early-phase): Small, short-duration studies reported improved hair counts/diameter with acceptable local tolerability and no meaningful changes in serum hormones at studied doses. Full peer-reviewed datasets remain limited compared with minoxidil/finasteride.
Evidence quality note: Signals are promising but preliminary. There are no contemporary, large, randomized Phase 3 trials; long-term safety and durability are unknown.
5. Where it might fit (conceptually)
| Scenario | Rationale | Caveats |
|---|---|---|
| Men intolerant to 5-ARIs | Keep DHT systemic effects intact while blocking AR locally | Efficacy may be less than oral 5-ARI; purity variability |
| Stack with minoxidil | Orthogonal mechanisms (growth promotion + AR block) | Additive irritation risk (EtOH/PG) |
| Micro-dose 5-ARI + RU | Lower systemic exposure while maintaining control | Unproven optimal ratios |
| Female AGA | Avoid systemic antiandrogens; local AR targeting | Pregnancy avoidance; data sparse |
6. Safety and Tolerability
-
Local: Erythema, burning, itch, dryness, contact dermatitis (often vehicle-related); consider propylene-glycol-free or liposomal vehicles.
-
Systemic (intended to be low): Early studies showed no significant changes in serum DHT, T, LH/FSH at studied doses; however, formulation and over-application can increase absorption.
-
Endocrine/sexual AEs: Much less likely than with oral 5-ARIs but not impossible if systemic exposure occurs.
-
Ocular: Avoid contact with eyes.
-
Women of child-bearing potential: Avoid use in pregnancy (class antiandrogen precaution).
-
Unknowns: Chronic use (>1–2 years), rare idiosyncratic reactions, long-term scalp microbiome effects.
-
Product quality risk: Gray-market powders/solutions show variable identity and stability; degradation or mislabeling is a real safety issue.
Comparative matrix (AGA therapies)
| Feature | RU58841 (topical AR antagonist) | Finasteride (oral 5-ARI) | Dutasteride (oral) | Minoxidil (topical) |
|---|---|---|---|---|
| Primary action | Blocks AR locally | ↓ Scalp/systemic DHT | Stronger DHT suppression | ↑ Anagen, vasodilatory |
| Systemic hormone change | Minimal (intended) | Yes (DHT ↓) | Yes (DHT ↓↓) | No |
| Sexual AEs risk | Low (intended) | Low–mod (systemic) | Mod (systemic) | None sexual |
| Evidence strength | Early-phase, limited | Robust RCTs | Strong (off-label AGA) | Robust RCTs |
| Use in women | Potential (caution) | Generally avoided premenopause | Avoided | Yes (2–5%) |
7. Regulatory Landscape
-
Not approved by FDA/EMA/PMDA for any indication.
-
Appears in old patents and early studies; current availability is research-chemical only in many regions.
-
No standardized, GMP-grade medicinal product exists for routine clinical prescribing.
8. Practical Use (harm-reduction guidance for research contexts)
-
Vehicle matters: Ethanol/propylene glycol improves penetration but raises irritation; newer PG-free, liposomal, or hydroalcoholic bases may improve comfort.
-
Application: Once daily to dry scalp, thin film over affected zones; avoid dripping onto face/neck.
-
Stacking: If combined with minoxidil, separate by ~10–15 min; if used with oral 5-ARI, consider lower 5-ARI dose.
-
Monitoring: Track photographs, hair counts/diameter (trichoscopy), and any systemic symptoms. Discontinue if persistent irritation or systemic side effects appear.
-
Sourcing caution: Only laboratories should handle verified material (identity by HPLC/LC-MS/NMR); avoid consumer self-experimentation with unverified products.
Selected References
-
Preclinical AGA models (hamster/macaque) demonstrating topical AR antagonism and follicular protection.
-
Early human studies and patent data showing hair-count improvements with minimal hormonal changes at studied doses.
-
Reviews on androgen signaling in hair follicles (TGF-β, DKK-1, DP cell pathways) and comparisons with 5-AR inhibitors and topical antiandrogens.
-
Formulation/permeation literature on scalp delivery and vehicle-driven absorption for antiandrogen topicals.
Researcher reviews
No reviews yet for this lot line. Verified purchasers can leave the first one.
Reviews
There are no reviews yet.